Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AGA2118 tested in healthy volunteers across ethnic groups

NCT ID NCT07361354

Knowledge-focused Sponsor: Angitia Incorporated Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 4 times

Summary

This early-stage study is testing a single dose of a drug called AGA2118 in 30 healthy adults of Japanese, Chinese, and Caucasian backgrounds. Researchers want to see how the drug moves through the body and if it causes any side effects. The goal is to gather basic safety and dosing information, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AGA2118
What this could lead to
If successful, this study could help determine the right dosing for future trials of AGA2118 in different ethnic groups.
What could go wrong
This is an early Phase 1 study in healthy volunteers, not patients. It focuses on drug levels and safety, not on treating any disease. Results may not predict effectiveness in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

28 people

The number who actually took part.

Started

Jan 2026

Finished

Sep 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy males or females, aged 18 to 65 years * 25-hydroxyvitamin D ≥30 ng/mL and agree to taking calcium and vitamin D supplements during the study * Meet the criteria for Japanese, Chinese, or Caucasian ethnicity Exclusion Criteria: * Participating or have participated in another clinical trial within the past 6 months * Any bone fracture within the past 6 months * History of myocardial infarction or stroke within the past 12 months * Malignancy within the past 5 years * Current hyper- or hypocalcemia * Pregnant or breastfeeding women, or women planning to become pregnant during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants Pharmacokinetic study

Contacts and locations

Locations

  • Los Angeles EPCU

    Glendale, California, 91206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.